论文部分内容阅读
目的:研究防治经皮腔内血管成形术(FFA)后再狭窄的药物。方法:20条杂种犬,随机分为3组:川芎嗪组(n=6),阿斯匹林组(n=5)和对照组(n=9)。狭窄术后1～2周肾动脉造影证实形成狭窄,6～8周后行肾动脉成形术(PTRA)。对照组于 PTRA 前及术后4h,两用药组于给药前、PTRA 前及术后4h 分别采集外周静脉血样做血小板聚集率、血栓素B_2(TXB_2)和6-酮.前列腺素F_(1α)(6-keto-PGF_(1α))测定。结果:两用药组给药前后自身比较血小板聚集率、TXB_2均显著降低,6-keto-PGF_(1α)显著升高;而 PTRA 前后自身比较上述指标的变化则无显著性差异。对照组 PTRA 前后自身比较 TXB_2和血小板聚集率显著升高,6-keto-PGF_(1α)则显著降低。组间比较,两用药组 PTRA 前后血小板聚集率、TXB_2均显著低于对照组,6-keto-PGF_(1α)则明显高于对照组,只有术前阿斯匹林组与对照组比较6-keto-PGF_(1α)差异不显著。两用药组组间比较上述指标在 PTRA 前后均无显著性差异。结论:川芎嗪可能是一种有效防治 PTA 后血栓闭塞性再狭窄的药物。
Objective: To study the prevention and treatment of drugs after percutaneous transluminal angioplasty (FFA) restenosis. Methods: Twenty mongrel dogs were randomly divided into three groups: Ligustrazine group (n=6), aspirin group (n=5) and control group (n=9). Renal angiography confirmed stenosis 1 to 2 weeks after stenosis, and renal arterioplasty (PTRA) was performed 6 to 8 weeks later. In the control group before and 4 hours after PTRA, peripheral blood samples were collected before treatment, before PTRA, and 4 hours after surgery for platelet aggregation, thromboxane B_2 (TXB_2) and 6-keto. Prostaglandin F_ (1α) (6-keto-PGF_(1α)) measurement. RESULTS: The platelet aggregation rate and TXB 2 were significantly reduced in the dual drug group before and after administration, and 6-keto-PGF 1 (1α) was significantly increased. There was no significant difference in the changes of the above indexes before and after PTRA. In the control group, TXB_2 and platelet aggregation rate were significantly increased before and after PTRA, and 6-keto-PGF_(1α) was significantly decreased. Between groups, the platelet aggregation rate and TXB_2 were significantly lower in the dual drug group before and after PTRA, and 6-keto-PGF_(1α) was significantly higher than in the control group. Only the preoperative aspirin group was compared with the control group. 6- The difference in keto-PGF_(1α) was not significant. There was no significant difference between the two groups in the above indicators before and after PTRA. Conclusion: Tetramethylpyrazine may be an effective drug to prevent thromboembolic restenosis after PTA.